Clinical Trials
19 trialsNCT07610551 2026-05-28
Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma
Air Force Military Medical University, China
Recruiting
NCT04862949 2025-12-12
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
Completed
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT05197504 2025-09-05
HCC
CHA University
Completed
NCT05525858 2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06780826 2025-01-17
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Recruiting
NCT04920981 2024-11-07
CLINATEZO
Intergroupe Francophone de Cancerologie Thoracique
Completed
NCT05717738 2024-06-13
CCGLC-008
Tongji Hospital
Recruiting
NCT05173298 2024-02-07
HCC
CHA University
Unknown
NCT06169904 2023-12-14
B7-Family Score in Urothelial Carcinoma
Shanghai Zhongshan Hospital
Completed
NCT05418660 2023-09-18
I-STOP
University of Milano Bicocca
Unknown
NCT05797493 2023-04-04
PICASSO
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT05609903 2022-11-08
Anastase
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Completed
NCT03790397 2022-06-03
OSIREX
Fundación GECP
Completed
NCT04465942 2021-08-23
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT03228368 2017-07-24
The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients
First Affiliated Hospital of Zhejiang University
Unknown